BridgeBio’s Attruby (acoramidis) is positioning itself as a formidable competitor in the transthyretin amyloid cardiomyopathy (ATTR-CM) market, with new pivotal trial data and indirect comparisons suggesting potential advantages over Pfizer’s long-standing standard-of-care therapy, Vyndamax (tafamidis). The findings, presented at the European Society of Cardiology’s 2026 Heart Failure conference and reported by ClinicalTrialsArean.com, underscore Attruby’s clinical efficacy and growing market momentum.
Clinical Efficacy and Mechanism
The Phase III ATTRibute-CM study demonstrated that twice-daily Attruby treatment effectively boosted and maintained wild-type transthyretin levels from day 28 through month 30. Wild-type transthyretin is the protein that causes ATTR-CM when it misfolds and aggregates in heart tissue. Patients receiving Attruby experienced a significant reduction in blood transthyretin variability compared to placebo, with this stabilization accounting for approximately 20% of the drug’s positive impact on all-cause mortality risk.
According to Duke University School of Medicine’s Dr. Senthil Selvaraj, this finding has important implications for disease management. “By linking transthyretin variability independently to mortality, we’re seeing a mechanistic signal that may help explain Attruby’s clinical benefit,” Selvaraj noted. This suggests that minimizing fluctuations in transthyretin levels may be as important as reducing overall protein levels in modifying disease progression.
Improved Patient Outcomes
Beyond mechanism, Attruby demonstrated meaningful clinical benefits for ATTR-CM patients. The drug reduced the risk of outpatient worsening heart failure by 40% versus placebo, a particularly significant finding since heart failure deterioration is a strong predictor of death and hospitalization in this patient population. In Europe, where Bayer markets the drug as Beyonttra, these outcomes have validated its therapeutic potential in frontline treatment.
Competitive Positioning Against Vyndamax
An indirect comparison based on the ATTRibute-CM study suggests Attruby may outperform Pfizer’s established therapy. According to a matching-adjusted indirect comparison, Attruby demonstrated a 34% reduction in cardiovascular hospitalizations relative to Vyndamax, while maintaining a comparable safety profile. The drug also showed a favorable mortality trend, exhibiting a 28% hazard reduction in all-cause mortality versus tafamidis.
However, it is important to note that BridgeBio has not conducted a direct head-to-head study against Vyndamax, meaning definitive conclusions about comparative efficacy cannot yet be drawn from these indirect analyses.
Competitive Landscape
Currently, Attruby, Vyndamax, and Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) are the only FDA-approved ATTR-CM treatments, though pipeline candidates from Ionis Pharmaceuticals, Novo Nordisk, and Intellia Therapeutics are advancing through late-stage development. In a significant development, Pfizer reached settlements extending Vyndamax’s US patent protection to 2031, which analysts viewed as a mixed outcome for BridgeBio’s competitive position.
As the ATTR-CM market continues to expand, Attruby’s clinical data and market performance suggest it has successfully established itself as a viable and compelling therapeutic option for patients and prescribers seeking effective cardiac amyloidosis management.
